CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Merck & Cie v. Watson Laboratories Inc.

1:13-cv-01272

Overview

Case Number 1:13-cv-01272
Filing Date 2013-07-23
Status Terminated
Termination Date 2016-08-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Watson Laboratories Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Merck & Cie Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (1): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2015-10-08
1:15-cv-00899

Merck & Cie v. Lupin Ltd.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6441168
Stable crystalline salts of 5-methyltetrahydrofolic acid
Filed: 2000-04-17
Issued: 2002-08-27
Expired (Term Ended) +834d PTA
Expires: 2022-07-30

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+834 days) / Cellect Scrutiny β€” Over 834 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Claim Construction / Markman Filing 3 Procedural / Extension Motion 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
STIPULATION and Order Regarding Infringement and Claim Construction by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (...
Entry #37 • 2014-02-19 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER Regarding Infringement and Claim Construction of U.S. Patent NO. 6,441,168 (*the May 29,2014, Markman hearing has been removed from the Court calendar). S...
Entry #38 • 2014-02-19 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for parties to submit Joint Claim Chart to February 21, 2014 - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck...
Entry #36 • 2014-02-14 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 4/23/2014. Amended Pleadings due by 4/23/201...
Entry #20 • 2013-10-22 Document →

Docket Entries

(63 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Actavis Inc., Watson Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1333903.) - filed by Merck & Cie, Bayer Pharma AG, Bayer HealthCare Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(cla, ) (Entered: 07/23/2013)

Entry #1 • 2013-07-23
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Actavis Inc., Watson Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1333903.) - filed by Merck & Cie, Bayer Pharma AG, Bayer HealthCare Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(cla, ) (Entered: 07/23/2013)

Entry #1 • 2013-07-23
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Actavis Inc., Watson Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1333903.) - filed by Merck & Cie, Bayer Pharma AG, Bayer HealthCare Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(cla, ) (Entered: 07/23/2013)

Entry #1 • 2013-07-23
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cla, ) (Entered: 07/23/2013)

Entry #2 • 2013-07-23
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/20/13. Date of Expiration of Patent: 4/17/20.Thirty Month Stay Deadline: 12/20/2015. (cla, ) (Entered: 07/23/2013)

Entry #3 • 2013-07-23
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc